What inflammatory bowel disease is
Inflammatory bowel disease (IBD) is a group of chronic conditions characterised by inflammation of the gastrointestinal tract. The two main forms are Crohn’s disease and ulcerative colitis.
Crohn’s disease can affect any part of the gastrointestinal tract from mouth to anus, typically involves all layers of the bowel wall (transmural inflammation), and follows a pattern of flare-ups and remissions. Symptoms include abdominal pain, persistent diarrhoea, fatigue, weight loss, and in some cases fistulas or abscesses. Ulcerative colitis is limited to the colon and rectum, involves only the mucosal layer, and causes bloody diarrhoea, urgency, and abdominal pain.
IBD is distinct from irritable bowel syndrome (IBS), which is a functional disorder without visible inflammation or structural damage. IBD is diagnosed through endoscopy, imaging, and histology. Standard treatments include aminosalicylates, corticosteroids, immunomodulators, and biologic therapies targeting tumour necrosis factor, integrins, or interleukins.
The endocannabinoid system is distributed throughout the gut. CB1 receptors are present on enteric nerves and epithelial cells; CB2 receptors are found on immune cells and are upregulated during intestinal inflammation. This distribution provides a biological rationale for studying cannabinoids in IBD.
Cannabis research on Inflammatory bowel disease
The majority are ISMOKE magazine articles from 2011-2012 containing personal accounts and anecdotal reports. One excerpt references a patient survey reporting that cannabis-using Crohn’s patients described fewer stools per day, fewer flare-ups, and reduced immunosuppressive medication use. This is a human observational finding, not a controlled trial result, but it is consistent with data from the published literature. The evidence base also contains botanical and advocacy publications without clinical evidence.
The published medical literature contains human clinical trials, systematic reviews, and human tissue studies.
A systematic review of THC-containing cannabis for IBD, published in 2026, synthesised human studies and reported conflicting findings. In this review of human clinical and observational studies, some trials found that THC improved clinical symptoms in Crohn’s disease while others did not demonstrate benefit over placebo.
An overview of systematic reviews, published in 2026, noted low to moderate certainty of evidence of benefit for cannabis derivatives in ulcerative colitis, drawn from systematic reviews of randomised controlled trials.
A cross-sectional survey of 229 gastroenterology outpatients with IBD, published in 2026, found that 10.5% used CBD, primarily for anxiety rather than for gastrointestinal symptoms. In this human observational study, the most common reason for CBD use was anxiety, not IBD activity.
A human tissue study of endocannabinoid system gene expression in IBD mucosa, published in 2026, found altered expression of cannabinoid receptor and enzyme genes in inflamed versus non-inflamed intestinal tissue. This human observational finding confirms that the endocannabinoid system is altered at the tissue level in active IBD but does not establish that administering cannabinoids affects disease activity.
Earlier randomised controlled trials in the published literature have tested THC in Crohn’s disease. A 2013 double-blind trial of THC-rich cannabis in 21 patients with active Crohn’s disease reported that 45% of the THC group achieved clinical remission versus 10% on placebo. However, a follow-up trial in 2018 found no difference between THC and placebo on endoscopic remission, the more objective measure of disease activity.
Animal research has demonstrated that CB1 and CB2 receptor activation reduces intestinal inflammation, decreases gut permeability, and modulates immune responses in rodent colitis models. CB2 agonists in particular have shown consistent anti-inflammatory effects in animal studies of IBD. These findings provide biological plausibility but do not constitute human treatment evidence.
Compounds studied for Inflammatory bowel disease
THC has been tested in human randomised controlled trials for Crohn’s disease. Some trials found improvement in clinical symptoms; a trial measuring endoscopic remission did not. A 2026 systematic review characterised the human evidence as conflicting.
CBD has been studied in animal models of colitis, where it reduced inflammation and oxidative stress. A human cross-sectional survey found that IBD patients who use CBD do so mainly for anxiety. There are no completed human randomised controlled trials of isolated CBD for IBD with published results.
CBG has been tested in animal models of colitis, where it reduced inflammation and protected intestinal barrier function. No human clinical trial of CBG for IBD has been completed.
Beta-caryophyllene is a selective CB2 agonist. Since CB2 activation reduces gut inflammation in animal models, there is a plausible mechanistic link, but no human IBD trial of beta-caryophyllene exists.
Limonene has demonstrated anti-inflammatory effects in cell and animal studies. Human evidence for limonene in IBD is absent.
Myrcene has been studied in animal pain and inflammation models. There are no human IBD trials of myrcene.
Limits of the evidence for Inflammatory bowel disease
The human evidence for cannabinoids in IBD contains a pattern that appears across several trials: clinical symptoms improve in some studies, but more objective measures such as endoscopic appearance and inflammatory markers do not. This divergence may reflect cannabinoid effects on pain perception, motility, and wellbeing rather than on the underlying inflammatory process.
The largest and most rigorous randomised controlled trials of THC in Crohn’s disease enrolled 21 and 46 patients. These are small studies from which firm conclusions cannot be drawn.
No completed trial has tested whether cannabinoids maintain remission, prevent post-surgical recurrence, or heal fistulas in Crohn’s disease. The long-term safety of regular cannabinoid use in people with IBD, including effects on nutritional status, intestinal permeability, and risk of stricture or obstruction, has not been studied systematically.
IBS is not the same condition as IBD, and evidence for cannabinoids in IBD should not be assumed to apply to IBS. The endocannabinoid deficiency hypothesis proposes shared mechanisms, but this has not been validated in controlled human studies.
The evidence base contains anecdotal reports and a patient survey but no peer-reviewed clinical research. All clinical evidence was sourced from PubMed.
Sources
1. Jugl S, Okine R, Goodin AJ, Brown JD. Effectiveness of THC-containing cannabis for inflammatory bowel disease: a systematic review. Journal of Cannabis Research. 2026;8:45. Study record
2. Leite Pacheco R, de Oliveira Cruz Latorraca C, Martimbianco ALC, Riera R. Efficacy and safety of cannabis derivatives and their synthetic analogs: overview of systematic reviews. Phytotherapy Research. 2026;40(6):3475-3491. Study record
3. Fatakhova K, Narula N, Marshall JK, et al. Cannabidiol use in inflammatory bowel disease: insights from a gastroenterology outpatient population. JGH Open. 2026;10(4):e70402. Study record
4. Pelisenco IA, Zolin GJP, Deda O, et al. Altered endocannabinoid system gene expression in inflammatory bowel disease mucosa: new perspectives in inflammatory bowel disease management. World Journal of Gastrointestinal Endoscopy. 2026;18(2):113576. Study record
5. Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clinical Gastroenterology and Hepatology. 2013;11(10):1276-1280. Study record
